A third dose of COVID-19 vaccine offered essential workers some protection from developing long COVID during Omicron variant predominance, according to a new study in The Journal of Infectious Diseases.
New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.
As H5N1 bird flu continues to spread around the US, health officials recently found that 7 percent of dairy workers tested on farms in two states had evidence of recent infection — and some had signs of infection even when they didn’t feel sick.
Seasonal influenza epidemics impose substantial burdens on health care systems and cause >5 million hospitalizations of adults each year. The current approach to influenza vaccine development requires comprehensive surveillance of circulating strains, which are constantly moving from continent to continent....
This year's headlines on COVID-19 featured new research on COVID-related mortality, post-acute sequelae of infection, vaccine safety, and potential therapeutics.
Recent Comments